The service confirms where the patient is located and routes the visit to a clinician authorized in that jurisdiction. The clinician may prescribe an FDA-approved medicine, recommend another plan, refer, or decline to prescribe.
HHS licensure guide ↗
Clinician-led telehealth · approved-product first
Care that starts with clinical fit.
Explore FDA-approved prescription medicines through an eligibility-first telehealth review—without confusing clinical care with Peakonic’s separate research catalog.
01 Eligibility before payment02 No prescription guarantee03 Follow-up built in
Popular FDA-approved pathways
Wegovy®SemaglutideClinical review visualNot dispensed packaging
Zepbound®TirzepatideClinical review visualNot dispensed packaging
Illustrative clinical-review visuals only—not dispensed packaging. FDA approval belongs to the named manufacturer product, indication, dose, and presentation.
Telehealth starts here · Step 1 of 4
Check your visit fit.
Start with where you will be during the visit and what you want help with. The clinician must be authorized to practice where you are located at the time of the visit. Do not enter health details in this prototype.
Private by designNo payment collectedNo prescription guaranteed
Telehealth eligibility screen
Where should we start?
A licensed clinician must determine whether telehealth and any prescription are appropriate.
After clinician review
Telehealth is the care visit. 503A and 503B describe compounding pathways.
Section 503A generally applies when a state-licensed pharmacy, federal facility, or licensed physician compounds for an identified individual patient based on a valid prescription and every applicable federal and state condition is met.
FDA 503A requirements ↗A 503B outsourcing facility compounds sterile drugs under licensed-pharmacist supervision and may supply with or without patient-specific prescriptions when section 503B conditions are met. It is subject to CGMP requirements and FDA risk-based inspection.
FDA 503B explanation ↗Important: Compounded drugs are not FDA-approved. FDA recommends an approved drug when one is available and appropriate. Shortage status or a permitted bulk substance may affect whether compounding is allowed, but does not convert a compounded drug into an FDA-approved product or guarantee availability.
Clinical careClinician review → lawful prescription routeIndependent care cart
Never mixedResearch catalogResearch-use products → no clinical claimIndependent research cartOpen research storefront ↗
Current FDA data audit · 73 verified medicine groups
FDA-approved peptide medicine reference.
Browse verified U.S. product records, open the details, then add a review request. This broad clinical reference includes peptide drugs and closely related peptide/protein medicines; it excludes antibiotics, vaccines, enzymes, and non-U.S. approvals. A licensed clinician—not the storefront—decides whether telehealth, referral, or a prescription is appropriate.
Tymlos®abaloparatideClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Tymlos®
abaloparatide
See more information ↗
Parathyroid-hormone-related peptide analog approved for product-specific osteoporosis indications.
- Presentation
- Prefilled injection pen
- Review route
- Specialist prescription review
Scenesse®afamelanotideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Scenesse®
afamelanotide
See more information ↗
Melanocortin analog approved for a specific phototoxicity indication in erythropoietic protoporphyria.
- Presentation
- Subcutaneous implant
- Review route
- Specialist center referral
Giapreza®angiotensin II acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Giapreza®
angiotensin II acetate
See more information ↗
Vasopressor peptide approved for tightly supervised treatment of distributive shock.
- Presentation
- Intravenous infusion
- Review route
- Hospital-only review
Angiomax® / bivalirudinbivalirudinClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Angiomax® / bivalirudin
bivalirudin
See more information ↗
Direct thrombin-inhibitor peptide with approved procedural anticoagulation products.
- Presentation
- Intravenous injection
- Review route
- Specialist or facility review
Vyleesi®bremelanotide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Vyleesi®
bremelanotide acetate
See more information ↗
Approved for a specific sexual-health indication in certain premenopausal women—not general performance or tanning use.
- Presentation
- Single-dose autoinjector
- Review route
- Telehealth eligibility review
Hepcludex®bulevirtide-gmodClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Hepcludex®
bulevirtide-gmod
See more information ↗
Lipopeptide entry inhibitor approved for chronic hepatitis delta virus infection in specified adults.
- Presentation
- Subcutaneous injection
- Review route
- Hepatology or infectious-disease review
Miacalcin® / calcitonin-salmoncalcitonin salmonClinical review visualNot dispensed packaging
Visit estimateFrom $179FDA-approved product record
Miacalcin® / calcitonin-salmon
calcitonin salmon
See more information ↗
Calcitonin peptide products have exact, route-specific approved indications and labeling.
- Presentation
- Nasal spray or injection
- Review route
- Prescription review
Cetrotide®cetrorelix acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Cetrotide®
cetrorelix acetate
See more information ↗
GnRH antagonist approved for controlled ovarian-stimulation protocols.
- Presentation
- Subcutaneous injection kit
- Review route
- Fertility-specialist review
Acthar® Gel / Cortrophin® Gelrepository corticotropinClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Acthar® Gel / Cortrophin® Gel
repository corticotropin
See more information ↗
ACTH-family products have narrow, product-specific approved indications and extensive safety labeling.
- Presentation
- Repository injection
- Review route
- Specialist prescription review
Acthrel®corticorelin ovine triflutateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Acthrel®
corticorelin ovine triflutate
See more information ↗
Corticotropin-releasing hormone peptide approved for a specialized diagnostic test used in evaluating ACTH-dependent Cushing syndrome.
- Presentation
- Intravenous diagnostic injection
- Review route
- Endocrinology diagnostic referral
Cortrosyn®cosyntropinClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Cortrosyn®
cosyntropin
See more information ↗
Synthetic ACTH fragment approved as a diagnostic agent for adrenal-function testing.
- Presentation
- Injection for diagnostic testing
- Review route
- Diagnostic or facility review
Zegalogue®dasiglucagon hydrochlorideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Zegalogue®
dasiglucagon hydrochloride
See more information ↗
Glucagon analog approved for severe hypoglycemia in specified patients.
Availability: FDA approval record verified; current commercial availability must be confirmed.
- Presentation
- Prefilled syringe or autoinjector
- Review route
- Prescription review
Firmagon®degarelix acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Firmagon®
degarelix acetate
See more information ↗
GnRH antagonist approved for advanced prostate cancer.
- Presentation
- Subcutaneous depot injection
- Review route
- Oncology or urology review
DDAVP® / desmopressin productsdesmopressin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
DDAVP® / desmopressin products
desmopressin acetate
See more information ↗
Vasopressin analog products have route- and indication-specific approvals; formulation substitution is unsafe.
- Presentation
- Product-specific tablets, spray, or injection
- Review route
- Prescription review
Terlivaz®terlipressin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Terlivaz®
terlipressin acetate
See more information ↗
Vasopressin analog approved for adults with hepatorenal syndrome involving rapid reduction in kidney function.
- Presentation
- Intravenous injection
- Review route
- Hospital or hepatology review
Natrecor®nesiritideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Natrecor®
nesiritide
See more information ↗
Recombinant B-type natriuretic peptide with an FDA approval record for acute decompensated heart failure.
Availability: FDA approval record verified; listed products are discontinued and current availability must be confirmed.
- Presentation
- Intravenous infusion
- Review route
- Hospital-only review
Trulicity®dulaglutideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Trulicity®
dulaglutide
See more information ↗
Long-acting GLP-1 receptor agonist approved for product-specific diabetes and cardiovascular-risk indications.
- Presentation
- Prefilled injection pen
- Review route
- Telehealth eligibility review
Forzinity™elamipretide hydrochlorideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Forzinity™
elamipretide hydrochloride
See more information ↗
Mitochondria-targeting tetrapeptide granted accelerated approval for Barth syndrome in eligible patients.
- Presentation
- Subcutaneous injection
- Review route
- Rare-disease specialist review
Fuzeon®enfuvirtideClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Fuzeon®
enfuvirtide
See more information ↗
HIV fusion-inhibitor peptide with an FDA approval record for use as part of combination antiretroviral therapy.
Availability: FDA approval record verified; current commercial availability must be confirmed.
- Presentation
- Subcutaneous injection
- Review route
- Infectious-disease specialist review
Kalbitor®ecallantideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Kalbitor®
ecallantide
See more information ↗
Kunitz-domain peptide approved for acute hereditary-angioedema attacks in specified patients.
- Presentation
- Subcutaneous injection administered by a health professional
- Review route
- Specialist or facility review
Lipfendra™enlicitide decanoateClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Lipfendra™
enlicitide decanoate
See more information ↗
Oral cyclic peptide PCSK9 inhibitor approved in July 2026 for specified adults with elevated LDL cholesterol.
- Presentation
- Oral tablet
- Review route
- Telehealth eligibility review
Eptifibatide productseptifibatideClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Eptifibatide products
eptifibatide
See more information ↗
Cyclic heptapeptide antiplatelet medicines approved for acute coronary and procedural settings.
- Presentation
- Intravenous injection
- Review route
- Hospital or cardiology review
Parsabiv®etelcalcetideClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Parsabiv®
etelcalcetide
See more information ↗
Calcimimetic peptide approved for secondary hyperparathyroidism in adults receiving hemodialysis.
- Presentation
- Intravenous injection after dialysis
- Review route
- Dialysis-center review
Byetta® / exenatide productsexenatide syntheticClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Byetta® / exenatide products
exenatide synthetic
See more information ↗
GLP-1 receptor agonist products have product-specific diabetes indications and presentations.
- Presentation
- Product-specific injection pen
- Review route
- Telehealth eligibility review
Fyremadel® / ganirelixganirelix acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Fyremadel® / ganirelix
ganirelix acetate
See more information ↗
GnRH antagonist approved for controlled ovarian-stimulation protocols.
- Presentation
- Subcutaneous prefilled syringe
- Review route
- Fertility-specialist review
Baqsimi® / Gvoke® / glucagonglucagonClinical review visualNot dispensed packaging
Visit estimateFrom $179FDA-approved product record
Baqsimi® / Gvoke® / glucagon
glucagon
See more information ↗
Approved glucagon products treat severe hypoglycemia, with route- and device-specific instructions.
- Presentation
- Nasal powder, autoinjector, syringe, or kit
- Review route
- Prescription review
Zoladex®goserelin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Zoladex®
goserelin acetate
See more information ↗
GnRH agonist implant with product-specific oncology and gynecologic indications.
- Presentation
- Subcutaneous implant
- Review route
- Specialist prescription review
Supprelin LA®histrelin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Supprelin LA®
histrelin acetate
See more information ↗
GnRH agonist implant approved for central precocious puberty.
- Presentation
- Subcutaneous implant
- Review route
- Pediatric endocrinology review
Firazyr® / icatibanticatibant acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Firazyr® / icatibant
icatibant acetate
See more information ↗
Bradykinin B2-receptor antagonist peptide approved for acute hereditary-angioedema attacks in adults.
- Presentation
- Prefilled subcutaneous syringe
- Review route
- Specialist prescription review
Copaxone® / Glatopa®glatiramer acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Copaxone® / Glatopa®
glatiramer acetate
See more information ↗
Synthetic polypeptide mixture approved for relapsing forms of multiple sclerosis.
- Presentation
- Prefilled subcutaneous syringe or autoinjector
- Review route
- Neurology specialist review
Icotyde™icotrokinra hydrochlorideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Icotyde™
icotrokinra hydrochloride
See more information ↗
Oral cyclic peptide IL-23 receptor antagonist approved in March 2026 for specified psoriasis patients.
- Presentation
- Oral tablet
- Review route
- Dermatology review
Insulin product familyhuman insulin and insulin analogsClinical review visualNot dispensed packaging
Visit estimateFrom $129FDA-approved product record
Insulin product family
human insulin and insulin analogs
See more information ↗
Many FDA-approved insulins exist; concentration, device, interchangeability, and indication are product-specific.
- Presentation
- Vials, pens, and product-specific devices
- Review route
- Diabetes care review
Awiqli® FlexTouch®insulin icodecClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Awiqli® FlexTouch®
insulin icodec
See more information ↗
Once-weekly basal insulin analog approved in March 2026 for specified adults with diabetes.
- Presentation
- Prefilled injection pen
- Review route
- Diabetes care review
Somatuline Depot® / lanreotidelanreotide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Somatuline Depot® / lanreotide
lanreotide acetate
See more information ↗
Somatostatin analog products have specific neuroendocrine and acromegaly indications.
- Presentation
- Deep subcutaneous injection
- Review route
- Endocrinology or oncology review
Lupron Depot® / Eligard® / Fensolvi®leuprolide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Lupron Depot® / Eligard® / Fensolvi®
leuprolide acetate
See more information ↗
Leuprolide products have distinct indications, dosing schedules, and delivery systems.
- Presentation
- Product-specific depot presentation
- Review route
- Specialist prescription review
Linzess®linaclotideClinical review visualNot dispensed packaging
Visit estimateFrom $149FDA-approved product record
Linzess®
linaclotide
See more information ↗
Guanylate-cyclase-C agonist peptide approved for product-specific chronic constipation disorders.
- Presentation
- Oral capsule
- Review route
- Telehealth eligibility review
Victoza® / Saxenda® / liraglutideliraglutideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Victoza® / Saxenda® / liraglutide
liraglutide
See more information ↗
GLP-1 receptor agonist products have distinct diabetes or chronic weight-management indications.
- Presentation
- Prefilled injection pen
- Review route
- Telehealth eligibility review
Adlyxin® / Soliqua®lixisenatideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Adlyxin® / Soliqua®
lixisenatide
See more information ↗
GLP-1 receptor agonist products approved for product-specific diabetes use, including a fixed-ratio insulin combination.
- Presentation
- Prefilled injection pen
- Review route
- Diabetes care review
Lutathera®lutetium Lu 177 dotatateClinical review visualNot dispensed packaging
Visit estimateFrom $349FDA-approved product record
Lutathera®
lutetium Lu 177 dotatate
See more information ↗
Radiolabeled somatostatin analog approved for specified neuroendocrine tumors.
- Presentation
- Intravenous radiopharmaceutical
- Review route
- Nuclear-medicine or oncology referral
Netspot®gallium Ga 68 dotatateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Netspot®
gallium Ga 68 dotatate
See more information ↗
Radiolabeled peptide diagnostic approved for PET imaging of somatostatin-receptor-positive neuroendocrine tumors.
- Presentation
- Intravenous diagnostic radiopharmaceutical
- Review route
- Nuclear-medicine referral
Detectnet®copper Cu 64 dotatateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Detectnet®
copper Cu 64 dotatate
See more information ↗
Radiolabeled peptide diagnostic approved for PET localization of somatostatin-receptor-positive neuroendocrine tumors.
- Presentation
- Intravenous diagnostic radiopharmaceutical
- Review route
- Nuclear-medicine referral
Ga 68 edotreotide productsgallium Ga 68 edotreotideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Ga 68 edotreotide products
gallium Ga 68 edotreotide
See more information ↗
Radiolabeled somatostatin analog approved for PET imaging of somatostatin-receptor-positive neuroendocrine tumors.
- Presentation
- Intravenous diagnostic radiopharmaceutical
- Review route
- Nuclear-medicine referral
Locametz® / Illuccix® / Gozellix®gallium Ga 68 gozetotideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Locametz® / Illuccix® / Gozellix®
gallium Ga 68 gozetotide
See more information ↗
PSMA-targeted peptide-based radioligand approved for product-specific prostate-cancer PET imaging uses.
- Presentation
- Intravenous diagnostic radiopharmaceutical
- Review route
- Nuclear-medicine referral
OctreoScan®indium In 111 pentetreotideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
OctreoScan®
indium In 111 pentetreotide
See more information ↗
Radiolabeled somatostatin analog with an FDA approval record for scintigraphic localization of neuroendocrine tumors.
Availability: FDA approval record verified; current commercial availability must be confirmed.
- Presentation
- Intravenous diagnostic kit
- Review route
- Nuclear-medicine referral
Pluvicto®lutetium Lu 177 vipivotide tetraxetanClinical review visualNot dispensed packaging
Visit estimateFrom $349FDA-approved product record
Pluvicto®
lutetium Lu 177 vipivotide tetraxetan
See more information ↗
PSMA-targeted peptide-based radioligand approved for specified adults with metastatic prostate cancer.
- Presentation
- Intravenous radiopharmaceutical
- Review route
- Nuclear-medicine or oncology referral
Lumisight™pegulicianine acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Lumisight™
pegulicianine acetate
See more information ↗
Peptide-based fluorescent imaging agent approved as an adjunct for identifying residual cancer during certain breast lumpectomy procedures.
- Presentation
- Intravenous imaging agent
- Review route
- Surgical-facility referral
Synarel®nafarelin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $229FDA-approved product record
Synarel®
nafarelin acetate
See more information ↗
GnRH agonist nasal product with specific approved reproductive-endocrine indications.
- Presentation
- Nasal spray
- Review route
- Specialist prescription review
Yuviwel™navepegritideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Yuviwel™
navepegritide
See more information ↗
Long-acting C-type natriuretic peptide analog approved in February 2026 for eligible children with achondroplasia.
- Presentation
- Subcutaneous injection
- Review route
- Pediatric skeletal-dysplasia specialist review
Sandostatin® / Mycapssa® / octreotideoctreotide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Sandostatin® / Mycapssa® / octreotide
octreotide acetate
See more information ↗
Somatostatin analog products have formulation-specific endocrine and neuroendocrine indications.
- Presentation
- Injection, depot, oral capsule, or pen
- Review route
- Endocrinology or oncology review
Pitocin® / oxytocinoxytocinClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Pitocin® / oxytocin
oxytocin
See more information ↗
Approved oxytocin products are used in tightly controlled obstetric settings—not consumer peptide therapy.
- Presentation
- Injection for supervised clinical use
- Review route
- Hospital-only obstetric review
Yorvipath®palopegteriparatideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Yorvipath®
palopegteriparatide
See more information ↗
Prodrug of parathyroid hormone approved for hypoparathyroidism in adults.
- Presentation
- Prefilled injection pen
- Review route
- Endocrinology review
Signifor® / Signifor LAR®pasireotideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Signifor® / Signifor LAR®
pasireotide
See more information ↗
Somatostatin analog products approved for specific pituitary-disorder indications.
- Presentation
- Subcutaneous or depot injection
- Review route
- Endocrinology specialist review
Empaveli® / Syfovre®pegcetacoplanClinical review visualNot dispensed packaging
Visit estimateFrom $349FDA-approved product record
Empaveli® / Syfovre®
pegcetacoplan
See more information ↗
C3 inhibitor peptide products have distinct hematology and ophthalmology indications and routes.
- Presentation
- Subcutaneous infusion or intravitreal injection
- Review route
- Specialist prescription review
Aphexda®motixafortide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Aphexda®
motixafortide acetate
See more information ↗
Cyclic peptide CXCR4 antagonist approved with filgrastim for stem-cell mobilization before autologous transplant in multiple myeloma.
- Presentation
- Subcutaneous injection
- Review route
- Transplant-center or hematology review
Trulance®plecanatideClinical review visualNot dispensed packaging
Visit estimateFrom $149FDA-approved product record
Trulance®
plecanatide
See more information ↗
Guanylate-cyclase-C agonist peptide approved for specified chronic constipation disorders.
- Presentation
- Oral tablet
- Review route
- Telehealth eligibility review
Symlin®pramlintide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Symlin®
pramlintide acetate
See more information ↗
Amylin analog with an FDA approval record as adjunctive diabetes therapy.
Availability: FDA approval record verified; current commercial availability must be confirmed.
- Presentation
- Prefilled injection pen
- Review route
- Diabetes care review
ChiRhoStim® / secretinsecretinClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
ChiRhoStim® / secretin
secretin
See more information ↗
Secretin peptide products are approved for specific pancreatic diagnostic testing.
- Presentation
- Intravenous diagnostic injection
- Review route
- Diagnostic or facility review
Ozempic® / Rybelsus® / Wegovy®semaglutideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Ozempic® / Rybelsus® / Wegovy®
semaglutide
See more information ↗
Semaglutide brands have different FDA-approved indications, doses, and presentations; they are not interchangeable by name alone.
- Presentation
- Injection pens or oral tablets
- Review route
- Telehealth eligibility review
Imcivree®setmelanotide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Imcivree®
setmelanotide acetate
See more information ↗
Melanocortin-4 receptor agonist peptide approved for obesity caused by specified rare genetic conditions.
- Presentation
- Subcutaneous injection
- Review route
- Rare-disease specialist review
Increlex®mecasermin recombinantClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Increlex®
mecasermin recombinant
See more information ↗
Recombinant IGF-1 peptide/protein approved for severe primary IGF-1 deficiency in eligible pediatric patients.
- Presentation
- Subcutaneous injection
- Review route
- Pediatric endocrinology review
Growth-hormone product familysomatropin, lonapegsomatropin, somapacitan, and somatrogonClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Growth-hormone product family
somatropin, lonapegsomatropin, somapacitan, and somatrogon
See more information ↗
Approved growth-hormone products exist for narrow, product-specific indications; federal law separately restricts distribution for unapproved uses.
- Presentation
- Product-specific cartridges and injection systems
- Review route
- Endocrinology specialist review
Gattex®teduglutideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Gattex®
teduglutide
See more information ↗
GLP-2 analog approved for adults and certain pediatric patients with short bowel syndrome who need parenteral support.
- Presentation
- Subcutaneous injection kit
- Review route
- Gastroenterology specialist review
Forteo® / Bonsity® / teriparatideteriparatideClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Forteo® / Bonsity® / teriparatide
teriparatide
See more information ↗
Parathyroid-hormone analog products have exact osteoporosis indications and duration-of-use labeling.
- Presentation
- Prefilled injection pen
- Review route
- Specialist prescription review
Egrifta® productstesamorelin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Egrifta® products
tesamorelin acetate
See more information ↗
Tesamorelin has a specific FDA-approved indication; approval does not extend to generic research vials or other uses.
- Presentation
- Product-specific injection kit
- Review route
- Specialist prescription review
Mounjaro® / Zepbound®tirzepatideClinical review visualNot dispensed packaging
Visit estimateFrom $199FDA-approved product record
Mounjaro® / Zepbound®
tirzepatide
See more information ↗
Tirzepatide brands have distinct FDA-approved indications and exact current labels.
- Presentation
- Prefilled injection pen
- Review route
- Telehealth eligibility review
Trelstar® / Triptodur®triptorelin pamoateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Trelstar® / Triptodur®
triptorelin pamoate
See more information ↗
GnRH agonist depot products have distinct oncology and pediatric endocrine indications.
- Presentation
- Intramuscular depot injection
- Review route
- Specialist prescription review
Daybue®trofinetideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Daybue®
trofinetide
See more information ↗
Synthetic tripeptide analog approved for Rett syndrome in adults and pediatric patients two years of age and older.
- Presentation
- Oral solution or oral-powder stick
- Review route
- Neurology specialist review
Vasostrict® / vasopressinvasopressinClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Vasostrict® / vasopressin
vasopressin
See more information ↗
Vasopressin peptide products are approved for specific critical-care uses requiring monitored administration.
- Presentation
- Intravenous infusion
- Review route
- Hospital-only review
Voxzogo®vosoritideClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Voxzogo®
vosoritide
See more information ↗
C-type natriuretic peptide analog approved to increase linear growth in eligible children with achondroplasia.
- Presentation
- Subcutaneous injection
- Review route
- Pediatric skeletal-dysplasia specialist review
Prialt®ziconotide acetateClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Prialt®
ziconotide acetate
See more information ↗
Conotoxin-derived peptide approved for severe chronic pain through intrathecal infusion.
- Presentation
- Intrathecal infusion
- Review route
- Pain-specialist review
Korsuva®difelikefalin acetateClinical review visualNot dispensed packaging
Visit estimateFrom $249FDA-approved product record
Korsuva®
difelikefalin acetate
See more information ↗
D-amino-acid tetrapeptide kappa-opioid receptor agonist approved for moderate-to-severe pruritus in specified adults on hemodialysis.
- Presentation
- Intravenous injection after dialysis
- Review route
- Dialysis-center review
Istodax® / romidepsinromidepsinClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Istodax® / romidepsin
romidepsin
See more information ↗
Cyclic depsipeptide medicine approved for specific T-cell lymphoma indications.
- Presentation
- Intravenous infusion
- Review route
- Oncology specialist review
Zilbrysq®zilucoplan sodiumClinical review visualNot dispensed packaging
Visit estimateFrom $299FDA-approved product record
Zilbrysq®
zilucoplan sodium
See more information ↗
Cyclic peptide complement inhibitor approved for specified adults with generalized myasthenia gravis.
- Presentation
- Prefilled subcutaneous device
- Review route
- Neurology specialist review
Approval is product-specific. An approved active ingredient does not make a generic research vial, compounded copy, different salt, route, dose, or use FDA-approved. Prototype estimates are placeholders—not medication prices or quotes. Visit, insurance, manufacturer, and pharmacy costs vary. No prescription is guaranteed.
FDA 503A bulk-substance reference · Category 1
Category 1: Under FDA evaluation.
Nominated with enough support for FDA to evaluate and not placed on another list. The current entries shown here include NAD/NAD+, NADH, VIP, and non-injectable GHK-Cu. Informational only on Peakonic. Any compounding requires an eligible compounder and every applicable federal and state condition. This is not approval.
GHK-CuCategory 1
GHK-Cu
Except injectable routes of administration
Reference onlyNo medication checkout
See more information ↗
FDA bulk-substance nomination under evaluation; interim enforcement policy may apply to eligible compounders when every condition is met
Not FDA-approved and not a customer-facing treatment listing. This entry does not cover injectable GHK-Cu.
FDA category explanation ↗NAD+Category 1
NAD / NAD+
Nicotinamide Adenine Dinucleotide (NAD)
Reference onlyNo medication checkout
See more information ↗
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. NAD is a dinucleotide coenzyme, not a peptide. Category 1 is an interim compounding-policy status—not an approval, prescription indication, or retail authorization.
FDA category explanation ↗NADHCategory 1
NADH
Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH)
Reference onlyNo medication checkout
See more information ↗
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. This exact reduced disodium substance is a separate Category 1 entry and must not be generalized to every NAD formulation.
FDA category explanation ↗VIPCategory 1
Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide (VIP)
Reference onlyNo medication checkout
See more information ↗
Listed by FDA in Category 1 for 503A bulk-substance evaluation as of May 14, 2026
Not FDA-approved. Category 1 status does not establish safety, effectiveness, a labeled use, or a consumer sale pathway.
FDA category explanation ↗FDA 503A bulk-substance reference · Category 2
Category 2: Significant safety concerns.
FDA has identified potential significant safety risks while evaluating the nomination. Outside the Category 1 interim policy. Peakonic marks these entries Not for resale.
MK-677Category 2
Ibutamoren mesylate (MK-677)
Ibutamoren mesylate
Not for resaleNo cart or clinical offer
See more information ↗
Significant safety concerns identified by FDA
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗Kisspeptin-10Category 2
Kisspeptin-10
Kisspeptin-10
Not for resaleNo cart or clinical offer
See more information ↗
FDA has identified potential significant safety risks while evaluating the nomination
Not for resale. This is not an FDA-approved medicine and is outside the Category 1 interim policy.
FDA category explanation ↗FDA 503A bulk-substance reference · Category 3
Category 3: Inadequate nomination support.
The nomination did not include enough information for FDA to evaluate the substance. Outside the Category 1 interim policy. Peakonic marks these entries Not for resale.
Beta-NADCategory 3
Beta-NAD disodium salt trihydrate
Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. This Category 3 entry is chemically and legally distinct from the Category 1 NAD and NADH entries.
FDA category explanation ↗ARA-290Category 3
Cibinetide (ARA-290)
Cibinetide (ARA-290)
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion and no FDA-approved product identified.
FDA category explanation ↗GHRP-2Category 3
GHRP-2
Growth hormone-releasing peptide-2
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗GHRP-6Category 3
GHRP-6
Growth hormone-releasing peptide-6
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗L-CarnosineCategory 3
L-Carnosine
L-Carnosine
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. This exact FDA entry is L-Carnosine; the library’s separate Carnosine record is not treated as equivalent and remains off-list.
FDA category explanation ↗MGFCategory 3
Mechano growth factor (MGF)
Mechano growth factor (MGF)
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion and no FDA-approved product identified.
FDA category explanation ↗Secretin 99%Category 3
Secretin, human 99%
Bulk substance entry: Secretin, human 99%
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. This Category 3 bulk substance is not the same legal product as an FDA-approved, manufacturer-labeled secretin medicine.
FDA category explanation ↗ThymulinCategory 3
Thymulin acetate
Acetate form
Not for resaleNo cart or clinical offer
See more information ↗
Nomination did not include adequate support for FDA evaluation
Not for resale. No Category 1 interim enforcement discretion.
FDA category explanation ↗Separate status · not Category 1, 2, or 3
Uncategorized peptides.
These learning-library entries have no current Category 1, 2, or 3 listing verified in the stored snapshot. Future agency action is possible, but FDA has not announced approval dates for this group.
BPC-157Not in Categories 1–3
BPC-157
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug. Free-base and acetate forms received July 2026 PCAC review; committee review is not final FDA authorization.
Check current FDA information ↗CJC-1295Not in Categories 1–3
CJC-1295
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug; no current Category 1 pathway verified.
Check current FDA information ↗CardiogenNot in Categories 1–3
Cardiogen
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗CarnosineNot in Categories 1–3
Carnosine
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
Dietary/supplement and drug questions are product- and claim-specific; inclusion here does not classify every carnosine product as a drug.
Check current FDA information ↗CerebrolysinNot in Categories 1–3
Cerebrolysin
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; FDA warning-letter history includes compounded Cerebrolysin products.
Check current FDA information ↗CortexinNot in Categories 1–3
Cortexin
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived mixture with identity and biologic-source risks.
Check current FDA information ↗CrystagenNot in Categories 1–3
Crystagen
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; transcription/identity and evidence require confirmation.
Check current FDA information ↗Emideltide (DSIP)Not in Categories 1–3
Emideltide (DSIP)
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; free-base and acetate forms received July 2026 PCAC review without a final-list inference.
Check current FDA information ↗EpitalonNot in Categories 1–3
Epitalon
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; free-base and acetate forms received July 2026 PCAC review without final-list placement inferred.
Check current FDA information ↗EpithalaminNot in Categories 1–3
Epithalamin
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived extract/mixture.
Check current FDA information ↗IGF-1 LR3Not in Categories 1–3
IGF-1 LR3
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved IGF-1 LR3 human drug; it must not be conflated with FDA-approved mecasermin products.
Check current FDA information ↗IpamorelinNot in Categories 1–3
Ipamorelin
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Nomination withdrawn; no current Category 1 pathway
No FDA-approved human drug; FDA safety page states the acetate 503A nomination was withdrawn and identifies safety concerns.
Check current FDA information ↗KPVNot in Categories 1–3
KPV
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; FDA says it has not identified human exposure data for nominated compounded products.
Check current FDA information ↗LivagenNot in Categories 1–3
Livagen
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗MOTS-cNot in Categories 1–3
MOTS-c
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; July 2026 PCAC review is not final authorization.
Check current FDA information ↗Melanotan IINot in Categories 1–3
Melanotan II
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Nomination withdrawn; no current Category 1 pathway
No FDA-approved human drug; FDA identifies serious case reports and safety/impurity concerns. Distinct from bremelanotide.
Check current FDA information ↗OvagenNot in Categories 1–3
Ovagen
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; incidental transcript mention and limited foreign/preclinical evidence.
Check current FDA information ↗Pinealon (EDR)Not in Categories 1–3
Pinealon (EDR)
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug; evidence discussed is largely preclinical, foreign, or anecdotal.
Check current FDA information ↗RetatrutideNot in Categories 1–3
Retatrutide
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
Investigational; no FDA-approved retatrutide product as of the database date.
Check current FDA information ↗SemaxNot in Categories 1–3
Semax
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; FDA lists safety-information gaps and July 2026 PCAC review is not final authorization.
Check current FDA information ↗TB-500Not in Categories 1–3
TB-500
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Advisory review complete; final FDA determination not verified
No FDA-approved human drug; it is a fragment related to, but not the same as, full thymosin beta-4.
Check current FDA information ↗ThymalinNot in Categories 1–3
Thymalin
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; animal-derived mixtures add identity, contamination, and prion-risk questions.
Check current FDA information ↗ThymogenNot in Categories 1–3
Thymogen
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; limited foreign/preclinical evidence.
Check current FDA information ↗Thymosin alpha-1Not in Categories 1–3
Thymosin alpha-1
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
Nomination withdrawn; no current Category 1 pathway
No current FDA-approved U.S. human drug identified; speaker's FDA-approval statement conflicts with current U.S. screening. FDA lists a withdrawn nomination and safety-information gaps.
Check current FDA information ↗Thymosin beta-4Not in Categories 1–3
Thymosin beta-4
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
Distinct from TB-500. No FDA-approved human thymosin beta-4 drug identified for this screening database.
Check current FDA information ↗Thymosin fraction 5Not in Categories 1–3
Thymosin fraction 5
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved human drug identified in this screening.
Check current FDA information ↗VilonNot in Categories 1–3
Vilon
Status may change only after a verified FDA update.
Not a clinical offerNo care cart or prescription pathway
See more information ↗
No current Category 1, 2, or 3 entry verified
No FDA-approved U.S. human drug; limited foreign/preclinical evidence.
Check current FDA information ↗Scope note: This is the intersection with Peakonic’s 42-compound learning library—not every substance in FDA’s full category documents.
The Peakonic model
Five gates before any clinical plan.
The care experience is designed around authorization, appropriate evaluation, transparent routing, and continuity—not a medication-first checkout.
Eligibility
Current state, age, visit goal, and emergency boundary.
Clinical intake
History, medications, allergies, records, and labs when needed.
Licensed review
An authorized clinician determines whether telehealth and treatment are appropriate.
Prescription decision
The outcome may be an FDA-approved medicine, another plan, referral, or no prescription.
Pharmacy and follow-up
If prescribed, the clinician sends the prescription to an eligible licensed pharmacy, with transparent costs and follow-up.
Primary-source standard
Clear claims need a visible source trail.
Medication approvals, compounding rules, and state telehealth requirements can change. Peakonic keeps the clinical route tied to current primary sources and separates it from the 42-compound research library.
51 jurisdictions42 research compounds52 exact research formsAug 22, 2026 data snapshot
FDADrugs@FDA data files — current approval records↗FDAMay 14, 2026 Category 1, 2, and 3 bulk-substance list↗FDA2026 warning letter addressing NAD+ and 503B eligibility↗FDA2026 product-specific guidances for generic peptide products↗FDANovel drug approvals for 2026↗FDACompounding and FDA questions and answers↗FDAHuman drug compounding laws: sections 503A and 503B↗HHSLicensing across state lines↗HHSPlanning a telehealth workflow↗
Separate storefront
Looking for the research catalog?
Research-use products have different labels, a different cart, and no clinical pathway. They never appear in the care cart.